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Background: The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher
overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with
bortezomib-rituximab versus rituximab. We report findings in high-risk patients (FL International Prognostic Index
[FLIPI] score ≥3, and high tumor burden by modified Groupe d’Etude des Lymphomas Folliculaires [GELF] criteria).
Methods: Patients aged ≥18 years with grade 1/2 FL, ≥1 measurable lesion, and documented relapse or
progression following prior therapy, rituximab-naïve or rituximab-sensitive, were enrolled at 164 centers in 29
countries across Europe, the Americas, and Asia-Pacific. Patients were randomized (1:1) to five 5-week cycles of
bortezomib-rituximab (bortezomib 1.6 mg/m2, days 1, 8, 15, and 22, all cycles; rituximab 375 mg/m2, days 1, 8, 15,
and 22, cycle 1, and day 1, cycles 2–5; N=336) or rituximab alone (N=340). Randomization was stratified by FLIPI
score, prior rituximab, time since last dose of anti-lymphoma therapy, and geographical region. The primary
endpoint of the study was PFS.
Results: 103 bortezomib-rituximab and 98 rituximab patients had high-risk FL. The ORR was 59% versus 37%
(p=0.002), the CR/CRu rate was 13% versus 6% (p=0.145), and the durable response rate was 45% versus 26%
(p=0.008) with bortezomib-rituximab versus rituximab. Median PFS was 9.5 versus 6.7 months (hazard ratio [HR]
0.667, p=0.012) with bortezomib-rituximab versus rituximab; median time to progression was 10.9 versus 6.8
months (HR 0.656, p=0.009); median time to next anti-lymphoma treatment was 14.8 versus 9.1 months (HR 0.762,
p=0.103); and the 1-year Overall Survival rate was 83.1% versus 76.6%. Overall, 51% of bortezomib-rituximab and
32% of rituximab patients reported grade ≥3 adverse events, including neutropenia (18%, 6%), anemia (4%, 5%),
diarrhea (8%, 0%), thrombocytopenia (5%, 2%), and sensory neuropathy (1%, 0%).
Conclusions: High-risk FL patients treated with bortezomib-rituximab had significantly higher ORR and longer PFS
than patients receiving rituximab alone, with greater clinical benefit than in the overall study population; additional
toxicity was acceptable and did not affect treatment feasibility.
Trial registration: The phase 3 LYM3001 trial is registered with ClinicalTrials.gov, with the identifier NCT00312845.
Keywords: Bortezomib, Follicular, High risk, Lymphoma, Rituximab* Correspondence: pierluigi.zinzani@unibo.it
1Institute of Hematology and Medical Oncology ‘L. & A. Seràgnoli’, University
of Bologna, Bologna, Italy
Full list of author information is available at the end of the article
© 2012 Zinzani et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Zinzani et al. Journal of Hematology & Oncology 2012, 5:67 Page 2 of 10
http://www.jhoonline.org/content/5/1/67Background
Follicular lymphoma (FL) is an incurable, indolent non-
Hodgkin’s lymphoma (NHL) subtype that follows a re-
lapsing course [1,2]. Although the introduction of new
therapies and treatment approaches over the past couple
of decades has improved progression-free survival (PFS)
[3] and overall survival (OS) [4,5], prognosis differs sig-
nificantly between patients according to multiple demo-
graphic and disease-related characteristics [5-10].
Adverse prognostic factors in FL include a high (≥3) FL
International Prognostic Index (FLIPI) score, represent-
ing patients aged >60 years, and/or with stage III–IV
disease, anemia, >4 involved nodal areas, and/or elevated
lactate dehydrogenase (LDH) [7,10,11], which has been
validated in the first-line setting [11] and shown to have
prognostic value at first relapse [10]. In addition, another
indicator of poor prognosis is a high tumor burden by
modified Groupe d’Etude des Lymphomas Folliculaires
(GELF) criteria [12], which includes involvement of ≥3
nodal sites of ≥3 cm diameter, any nodal/extranodal
tumor mass of ≥7 cm diameter, splenomegaly, pleural ef-
fusion or peritoneal ascites, leukocytes <1.0 x 109/L, or
platelets <100 x 109/L [12,13].
Patients with high-risk FL typically have a poor prog-
nosis, including a higher probability of relapse and lower
survival rates [7,10,11], and need better treatment
options [10,14,15]. These patients may particularly bene-
fit from novel, active regimens [10]. Rituximab is widely
used in previously untreated and relapsed FL [16], hav-
ing been shown to enhance the efficacy of chemothera-
peutic regimens [17-19] and to improve PFS when used
as maintenance therapy [3,20]. The proteasome inhibitor
bortezomib has shown single-agent activity in heavily
pretreated indolent lymphoma patients, with response
rates of up to 50% [21-23], and bortezomib plus rituxi-
mab has been shown to be active and generally well tol-
erated in phase 2 studies in FL and other NHL subtypes
[24-27].
The randomized, multicenter, international phase 3
LYM3001 trial compared bortezomib plus rituximab
with rituximab alone in 676 patients with relapsed,
rituximab-naïve or rituximab-sensitive FL [28]. Results
from the overall study population showed that the
addition of bortezomib resulted in prolonged PFS (pri-
mary endpoint; median 12.8 vs. 11.0 months, hazard
ratio [HR] 0.822; P=0.039), a higher overall response
rate (ORR; 63% vs. 49%, P<0.001), a higher complete
response (CR)/unconfirmed CR (CRu) rate (25% vs.
18%, P=0.035), and more durable responses. In this
ad-hoc subgroup analysis of LYM3001, we report the
activity and safety of rituximab ± bortezomib in
patients with high-risk disease, defining ‘high-risk’
patients as those having both a high (≥3) FLIPI score




In the overall study population, 139 patients in the
bortezomib-rituximab arm and 140 patients in the ritux-
imab arm had high FLIPI score (≥3), and 185 and 179
patients, respectively, had high tumor burden by modi-
fied GELF criteria [12]. Of these patients, 103 in the
bortezomib-rituximab arm and 98 in the rituximab arm
had high-risk FL per the definition for this subgroup
analysis (both FLIPI score ≥3 and high tumor burden by
modified GELF criteria [12]). High-risk patient demo-
graphics and baseline disease characteristics in the
intention-to-treat (ITT) population are shown in Table 1.
Demographics were consistent with those in the overall
study population; disease characteristics reflected the
high-risk nature of the patients compared with the over-
all study population [28]. Disease characteristics and
prior therapy exposure were generally balanced between
arms except for Ann Arbor staging and sex, with higher
proportions of patients with stage IV disease and males
in the bortezomib-rituximab arm.
Patient disposition and treatment exposure in the
safety population are shown in Table 2. One patient with
high-risk FL in the bortezomib-rituximab arm was not
treated and was excluded from the safety population.
Treatment exposure was generally comparable with that
in the overall study population [28], with patients in
both arms receiving a median of five cycles. However,
slightly lower proportions of patients in each arm com-
pleted all five cycles in this high-risk population (64%
and 53% in the bortezomib-rituximab and rituximab
arms, respectively) compared with in the overall popula-
tion (72% and 71%, respectively) [28], reflecting that
these patients were more challenging to treat. Among
the reasons for discontinuing treatment prior to com-
pleting five cycles, disease progression was less common
(25% vs. 39%) but adverse events (AEs) more common
(8% vs. 2%) in patients receiving bortezomib-rituximab
versus rituximab.
Efficacy
Bortezomib-rituximab resulted in a higher ORR and CR/
CRu rate than rituximab in patients with high-risk FL
(Table 3). Similarly, the rate of durable (≥6 months) re-
sponse was higher, and median duration of response
(DOR) in patients with CR/CRu was prolonged with
bortezomib-rituximab, although median DOR in all
responding patients appeared somewhat shorter.
In patients with high FLIPI score (≥3) regardless of
tumor burden, ORR was 64% versus 45% (odds ratio
0.459 [95% confidence interval (CI) 0.279, 0.756],
Table 1 Baseline characteristics of LYM3001 patients with high-risk FL (ITT population)
Bortezomib-rituximab (N=103) Rituximab (N=98)
Median age, years (range) 61 (38–83) 60 (21–84)
Aged >65 years, n (%) 31 (30) 25 (26)
Male, n (%) 53 (51) 42 (43)
Race, n (%)
White 78 (76) 65 (66)
Asian 20 (19) 29 (30)
Other 5 (5) 4 (4)
Region, n (%)
USA and Canada 8 (8) 10 (10)
European Union 34 (33) 28 (29)
Rest of the World* 61 (59) 60 (61)
ECOG performance status, n (%)
0 36 (35) 35 (36)
1 56 (54) 52 (53)
2 11 (11) 11 (11)
Ann Arbor Stage, n (%)
II 0 1 (1)
III 36 (35) 45 (46)
IV 67 (65) 52 (53)
High tumor burden by modified GELF criteria [12], n (%) 103 (100) 98 (100)
High (≥3) FLIPI score [7], n (%) 103 (100) 98 (100)
Elevated serum LDH, n (%) 70 (68) 61 (62)
Median time from initial diagnosis, months (range) 35.8 (2–233) 38.5 (1–197)
Number of prior lines of therapy, n (%)
1 43 (42) 35 (36)
2 25 (24) 31 (32)
≥3 35 (34) 32 (32)
Common prior therapies, n (%)
CHOP 41 (40) 40 (41)
CVP 35 (34) 23 (23)
Single-agent rituximab 17 (17) 13 (13)
Chlorambucil-prednisone 9 (9) 14 (14)
R-CHOP 10 (10) 12 (12)
R-CVP 9 (9) 12 (12)
Single-agent chlorambucil 10 (10) 10 (10)
Any prior rituximab therapy, n (%) 40 (39) 40 (41)
>1 year since last FL treatment, n (%) 53 (51) 48 (49)
Creatinine clearance >30–60 mL/min, n (%) 18 (17) 24 (24)
*Including 21%/12% from Russia, 10%/14% from People’s Republic of China, 9%/14% from India, and 9%/11% from Brazil in the bortezomib-rituximab/rituximab
arms.
ECOG, Eastern Cooperative Oncology Group; GELF, Groupe d’Etude des Lymphomas Folliculaires; FLIPI, Follicular Lymphoma International Prognostic Index; LDH,
lactate dehydrogenase.
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0.446 [95% CI 0.217, 0.916], p=0.026), and durable re-
sponse rate was 50% versus 32% (odds ratio 0.459 [95%
CI 0.277, 0.761], p=0.002) with bortezomib-rituximab
versus rituximab; in patients with high tumor burden
regardless of FLIPI score, ORR was 60% versus 41%(odds ratio 0.468 [95% CI 0.306, 0.717], p<0.001), CR/
CRu rate was 19% versus 10% (odds ratio 0.476 [95%
CI 0.254, 0.891], p=0.019), and durable response rate
was 45% versus 32% (odds ratio 0.581 [95% CI 0.377,
0.897], p=0.014) with bortezomib-rituximab versus
rituximab.
Table 2 Patient disposition and treatment exposure (safety population)
Bortezomib-rituximab (N=102) Rituximab (N=98)
Median number of cycles, n (range) 5 (1–5) 5 (1–5)
Median treatment duration, weeks (range) 25 (5–33) 25 (5–27)
Patients completing all 5 cycles, n (%) 65 (64) 52 (53)
Patients discontinuing prior to completing 5 cycles, n (%), due to: 37 (36) 46 (47)
Disease progression 26 (25) 38 (39)
AEs 8 (8) 2 (2)
Treatment-related 6 (6) 0
Death 1 (1) 1 (1)
Patient choice 2 (2) 4 (4)
Other reasons 0 1 (1)
Mean rituximab relative dose intensity, % 98 96
Mean bortezomib relative dose intensity, % 90 NA
AEs, adverse events; NA, not applicable.
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in the ITT population of high-risk patients, median PFS
was 9.5 months in the bortezomib-rituximab arm versus
6.7 months in the rituximab arm (HR 0.667, p=0.012)
(Figure 1A). Other outcomes were also longer with
bortezomib-rituximab versus rituximab, including: time
to progression (TTP; median 10.9 [95% CI 8.6, 11.8] vs.
6.8 [95% CI 4.5, 9.1] months; HR 0.656, p=0.009); time
to next anti-lymphoma treatment (TTNT; median 14.8
vs. 9.1 months; HR 0.762, p=0.103) (Figure 1B); and
treatment-free interval (TFI; median 9.2 [95% CI 6.2,
13.0] vs. 5.6 [95% CI 2.6, 10.4] months).
In patients with high FLIPI score (≥3) regardless of
tumor burden, median PFS was 11.4 versus 7.9 months
(HR 0.707, p=0.013), median TTP was 11.5 versus 9.0
months (HR 0.688, p=0.009), median TTNT was 17.1
versus 14.4 months (HR 0.760, p=0.067), and median
TFI was 12.8 versus 9.8 months (HR 0.788, p=0.110)
with bortezomib-rituximab versus rituximab; in patients
with high tumor burden regardless of FLIPI score, me-
dian PFS was 11.3 versus 8.4 months (HR 0.751,
p=0.019), median TTP was 11.4 versus 8.9 months (HR
0.747, p=0.018), median TTNT was 16.9 versus 13.5Table 3 Best response to treatment and durability of respons
Bortezomib-rituximab (N=96)
ORR, n (%) 57 (59)
CR/CRu*, n (%) 12 (13)
PR, n (%) 45 (47)
Stable disease, n (%) 24 (25)
Progressive disease, n (%) 15 (16)
Durable (≥6 months) response, n (%) 43 (45)
Median DOR, months 10.4
Median DOR (CR/CRu*), months 16.5
*Radiologic CR/CRu verified by bone marrow and lactate dehydrogenase.
CI, confidence interval; CR, complete response; CRu, unconfirmed CR; DOR, durationmonths (HR 0.751, p=0.024), and median TFI was 11.1
versus 8.5 months (HR 0.780, p=0.050) with bortezomib-
rituximab versus rituximab.
The 1-year OS rate was 83.1% (95% CI 75.8, 90.4) ver-
sus 76.6% (95% CI 68.0, 85.2) (HR 0.907, p=0.657) with
bortezomib-rituximab and rituximab, respectively. Me-
dian OS was 37.8 (95% CI 31.9, not estimable) versus
41.5 (95% CI 25.0, not estimable) months, with 43 (42%)
and 41 (42%) patients having died in the bortezomib-
rituximab and rituximab arms, respectively. In patients
with high FLIPI score (≥3) regardless of tumor burden,
the 1-year OS rate was 85.1% versus 82.8% (HR 0.952,
p=0.802) with bortezomib-rituximab versus rituximab;
respective rates in patients with high tumor burden re-
gardless of FLIPI score were 87.2% versus 84.3% (HR
0.981, p=0.919).Safety
The safety profiles of bortezomib-rituximab and rituxi-
mab in patients with high-risk FL are summarized in
Table 4. The rates of grade ≥3 AEs (51% vs. 32%), serious
AEs (22% vs. 16%), and AEs leading to treatmente (response-evaluable population)
Rituximab (N=95) Odds ratio (95% CI) P-value
35 (37) 0.399(0.223, 0.715) 0.002
6 (6) 0.472(0.169, 1.314) 0.145
29 (31) – –
32 (34) – –
28 (29) – –
25 (26) 0.440(0.240, 0.809) 0.008
12.1 – –
10.5 – –
of response; ORR, overall response rate; PR, partial response.
Figure 1 (A) PFS and (B) TTNT by treatment arm in patients
with high-risk FL.
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bortezomib-rituximab versus rituximab.
The most common AEs occurring at any grade in
≥15% of patients in either arm, or at grade ≥3 in ≥3%
of patients in either arm, are also listed in Table 4.
AEs were mostly mild or moderate (grade 1 or 2),
with only neutropenia (18% and 6% in the bortezomib-
rituximab and rituximab arms, respectively), infections
(16%, 7%), anemia (4%, 5%), diarrhea (8%, 0%), and
thrombocytopenia (5%, 2%) being reported at grade ≥3
in ≥5% patients in either arm. As shown in Table 4,
peripheral sensory neuropathy was reported in 15
patients in the bortezomib-rituximab arm, and was
grade 1 in 10 patients, grade 2 in four patients, and
grade 3 in one patient. Additionally, one patient in this
arm experienced grade 2 peripheral motor neuropathy.
The only serious AEs reported in ≥2% of patients
overall were pneumonia (5% in bortezomib-rituximab
arm, 1% in rituximab arm), febrile neutropenia (1%,
3%), neutropenia (2%, 2%), pyrexia (3%, 1%), and diar-
rhea (2%, 1%).Two deaths due to treatment-related AEs were
reported in the bortezomib-rituximab arm. These were
due to: septic shock (considered possibly related to both
bortezomib and rituximab); and bilateral pneumonia
(considered possibly related to bortezomib but not ritux-
imab) as well as acute respiratory failure and acute car-
diac failure, both considered unrelated to treatment [28].
In the rituximab arm, the one death due to an AE was
due to meningitis (considered unrelated to treatment)
[28].
Discussion
This ad-hoc subgroup analysis of the phase 3 LYM3001
study [28] of relapsed FL patients with the high-risk fea-
tures of both high FLIPI score (≥3) and high tumor bur-
den by modified GELF criteria [12] demonstrated a
number of key efficacy findings. In particular, we showed
that patients with high-risk FL treated with bortezomib-
rituximab had significantly higher response rates and
longer PFS than patients receiving rituximab alone. Fur-
thermore, while overall median DOR appeared similar
between arms, the durability of CR/CRu appeared
enhanced with the addition of bortezomib in this high-
risk patient population. The higher rate and durability of
CR/CRu with bortezomib-rituximab is notable, as CR
has been associated with improved outcomes in FL [29].
Additionally, the bortezomib-rituximab combination was
associated with a significantly longer TTP, and a longer
TTNT and associated TFI compared with rituximab
alone. No significant difference was seen in OS between
arms, as might be expected after a median follow-up of
3 years in a patient population with a typically indolent
disease course and a reported median OS from diagnosis
of up to approximately 14 years [4]. However, the 1-year
OS rate appeared slightly higher in the bortezomib-
rituximab arm, possibly due to an increased rate of pro-
gressive disease-related deaths in the rituximab arm
during this period.
Notably, the consistent relative clinical benefit with
bortezomib-rituximab versus rituximab in this subgroup
of high-risk patients was greater than that seen in the
overall study population [28], as indicated by HRs more
in favor of bortezomib-rituximab. For example, the HR
for PFS benefit with bortezomib-rituximab versus rituxi-
mab was 0.667 in these high-risk patients, compared
with 0.882 in the overall study population [28]. Similarly,
the odds ratios for ORR (0.399 vs. 0.569), CR/CRu rate
(0.472 vs. 0.665), and durable (≥6 months) response rate
(0.440 vs. 0.608), and the HRs for TTP (0.656 vs. 0.808),
TTNT (0.762 vs. 0.799), and OS (0.907 vs. 0.971) indi-
cated greater clinical benefit with bortezomib-rituximab
versus rituximab in the high-risk subgroup versus the
overall population. All these data suggest that the
addition of bortezomib might thus provide greater
Table 4 Safety profiles in high-risk FL patients (safety population)
AE, n (%) Bortezomib-rituximab(N=102) Rituximab(N=98)
Any AE 97 (95) 88 (90)
Any related AE 91 (89) 64 (65)
Any rituximab-related AE 70 (69) 64 (65)
Any bortezomib-related AE 85 (83) NA
Any grade ≥3 AE 52 (51) 31 (32)
Any serious AE 22 (22) 16 (16)
Any related serious AE 14 (14) 4 (4)
AE leading to treatment withdrawal 8 (8) 2 (2)
Deaths due to AEs 2 (2) 1 (1)
Most common AEs All grades Grade ≥3 All grades Grade ≥3
Diarrhea 50 (49) 8 (8) 11 (11) 0
Pyrexia 30 (29) 0 16 (16) 1 (1)
Fatigue 24 (24) 1 (1) 10 (10) 0
Neutropenia 21 (21) 18 (18) 11 (11) 6 (6)
Febrile neutropenia 1 (1) 1 (1) 3 (3) 3 (3)
Nausea 19 (19) 1 (1) 11 (11) 0
Abdominal pain 18 (18) 2 (2) 9 (9) 1 (1)
Decreased appetite 18 (18) 0 4 (4) 0
Infections 58 (57) 16 (16) 27 (28) 7 (7)
Upper respiratory tract 16 (16) 3 (3) 6 (6) 1 (1)
Herpes zoster 16 (16) 4 (4) 3 (3) 1 (1)
Pneumonia 6 (6) 3 (3) 4 (4) 3 (3)
Peripheral edema 15 (15) 2 (2) 13 (13) 2 (2)
Asthenia 15 (15) 1 (1) 11 (11) 4 (4)
Vomiting 15 (15) 0 11 (11) 2 (2)
Constipation 15 (15) 0 8 (8) 0
Peripheral sensory neuropathy 15 (15) 1 (1) 0 0
Dyspnea 13 (13) 1 (1) 10 (10) 4 (4)
Anemia 12 (12) 4 (4) 12 (12) 5 (5)
Thrombocytopenia 12 (12) 5 (5) 8 (8) 2 (2)
Leukopenia 7 (7) 3 (3) 12 (12) 2 (2)
AE, adverse event; NA, not applicable.
Table includes the most commonly reported AEs (≥15% at any grade or ≥3% grade ≥ 3 in either arm).
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fit in these patients who have a greater disease burden
or more proliferative FL.
The patient population included in these analyses
represented a true ‘high-risk’ subset of FL patients be-
cause they presented with both a high (≥3) FLIPI score
and high tumor burden, both of which are factors that
define cohorts of FL patients with disease that is high-
risk in nature. The poor prognostic nature of each of
these factors is supported by our efficacy analyses in the
specific individual subsets with high FLIPI score or with
high tumor burden, which demonstrated poorer out-
comes compared with in the overall study population
[28]; furthermore, our efficacy findings suggest that the
presence of both high FLIPI score and high tumorburden defines a population with poorer prognosis than
either factor alone. In supportive evidence from the lit-
erature, a FLIPI score of ≥3 has been associated with
poor prognosis in terms of PFS and OS in a number of
studies and analyses in both previously untreated and
relapsed FL patients treated with various different regi-
mens and modalities [7,9-11,30,31]. Similarly, the pres-
ence of a high tumor burden has been shown to be a
significant poor prognostic factor [13]. As previously
noted [28], there is no standard of care for relapsed FL,
with various different approaches recommended as pos-
sible therapeutic options in guidelines from the Euro-
pean Society for Medical Oncology [32] and the US
National Comprehensive Cancer Network [33], includ-
ing rituximab-chemotherapy and rituximab maintenance
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egy defined for FL patients with high FLIPI score and/or
high tumor burden, and thus identifying treatment
options offering relatively greater clinical benefit in
patients with these poor prognostic factors is of interest.
It is important to note that, per protocol, none of the
patients in LYM3001 were rituximab-refractory, another
factor representing a high-risk, difficult-to-treat popula-
tion. Nevertheless, non-clinical studies provide a ration-
ale for the potential utility of the bortezomib-rituximab
combination in this patient subset; some preclinical data
suggest that addition of bortezomib might be useful for
overcoming resistance in FL and for resensitizing
patients to treatment, including rituximab [34-36].
Regarding the safety profiles of bortezomib-rituximab
and rituximab alone in this subgroup analysis of patients
with high-risk FL, our findings reflect those in the over-
all study population but with somewhat elevated rates of
toxicity in these high-risk patients [28]. As would be
expected, bortezomib-rituximab was associated with
additional toxicity and rates of AEs were higher in the
combination arm compared with in the rituximab arm;
however this did not affect treatment feasibility, with
patients receiving a median of five cycles of treatment in
both arms and a higher proportion completing all five
planned cycles in the bortezomib-rituximab arm than in
the rituximab arm. As reported previously [28], the
addition of bortezomib to rituximab was associated with
peripheral neuropathy AEs, with 15% of patients in the
bortezomib-ritxumab arm experiencing peripheral sen-
sory neuropathy and 1% experiencing peripheral motor
neuropathy; however, only one grade 3 AE, of peripheral
sensory neuropathy, was reported in these high-risk
patients. As noted previously [28], this rate and severity
of peripheral neuropathy appeared limited compared
with previous reports in myeloma, which was likely asso-
ciated with the use of a weekly, instead of a twice-
weekly, bortezomib dosing regimen.Conclusions
In conclusion, bortezomib-rituximab appears an effective
regimen for the management of patients with relapsed
FL, offering clinical benefit compared with rituximab
alone in this high-risk subgroup of patients with the
poor prognostic features of high FLIPI score (≥3) and
high tumor burden. Further prospective validation of
these findings is warranted; an Eastern Cooperative
Oncology Group (ECOG) phase 2 study is currently
investigating bendamustine-rituximab with or without
bortezomib in patients with either high FLIPI score (≥3)
or high tumor burden by GELF criteria (NCT01216683).
Ongoing biomarker analyses of the LYM3001 study may
enable identification of specific patient subgroupsderiving greater benefit from bortezomib-rituximab ver-
sus rituximab treatment.
Methods
Patients and study design
The LYM3001 study design has been reported previously
[28]. LYM3001 was conducted at 164 centers in 29
countries across Europe, the Americas, and Asia-Pacific
[28]; patients were enrolled between April 10, 2006, and
August 12, 2008, and clinical data cut-off was June 15,
2010. Patients aged ≥18 years were enrolled in the study
if they met all of the following key inclusion criteria:
grade 1/2 FL (WHO criteria [37]) with ≥1 measurable le-
sion; documented relapse or progression following prior
therapy; rituximab-naïve or rituximab-sensitive (defined
as a response to and TTP of ≥6 months with prior
rituximab-containing therapy); ECOG performance sta-
tus ≤2; and no active central nervous system lymphoma.
Patients were excluded if they had grade ≥2 peripheral
neuropathy or neuropathic pain, or clinical evidence of a
transformation to an aggressive lymphoma, or had
received prior bortezomib. Review boards at all partici-
pating institutions approved the study, which was con-
ducted according to the Declaration of Helsinki and
International Conference on Harmonization Guidelines
for Good Clinical Practice. All patients provided written
informed consent.
Patients were randomized (1:1) to receive five 5-week
cycles consisting of bortezomib 1.6 mg/m2 on days 1, 8,
15, and 22, plus rituximab 375 mg/m2 on days 1, 8, 15,
and 22 in cycle 1 and on day 1 in cycles 2–5; or rituxi-
mab alone on the same schedule. Randomization was
stratified by FLIPI score (0–1 [low], 2 [intermediate], ≥3
[high]), prior rituximab therapy (yes, no), time since last
dose of anti-lymphoma therapy (≤1, >1 year), and geo-
graphical region (United States/Canada, European
Union, rest of the world). Patients were assigned based
on a computer-generated randomization schedule that
was pre-prepared by the study sponsor, as previously
described [28].
The primary endpoint of the study was PFS; the sec-
ondary endpoints included ORR, CR rate, DOR, TTP, 1-
year OS rate, and safety/tolerability. TTNT and TFI were
additional predefined endpoints of clinical benefit. As
reported previously [28], preplanned efficacy analyses
were conducted in patient subgroups defined according
to age, sex, ethnic origin, FLIPI score, prior rituximab,
prior lines of therapy, time since last dose of antilym-
phoma treatment, disease stage, and tumor burden.
Assessments
Patients’ FLIPI score and tumor burden were recorded
at screening based on the respective constitutive clinical
parameters. An independent radiology committee (IRC)
Zinzani et al. Journal of Hematology & Oncology 2012, 5:67 Page 8 of 10
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International Working Group Response Criteria [38].
Computed tomography (CT) scans with contrast (plus
magnetic resonance imaging [MRI] if required) were
performed at baseline, and every 10 weeks during and
following treatment until disease progression or death;
bone marrow aspiration and biopsy were performed for
confirmation of CR. Upon disease progression, patients
were followed every 3 months for survival, and subse-
quent anti-lymphoma therapy was recorded. AEs were
graded according to the National Cancer Institute’s
Common Terminology Criteria for AEs (NCI CTCAE)
version 3.0.Statistical analysis
For the overall LYM3001 study, the planned sample size
was 670 patients (accrual of 676 patients achieved), and
the target number of PFS events was 514 [28]. The study
was analyzed early, after 440 PFS events, per Independ-
ent Data Monitoring Committee recommendations as
the planned 514 events would probably have been un-
achievable within a reasonable timeframe due to very
low ongoing accumulation of PFS events [28].
PFS, TTP, TTNT, and OS were analyzed in the ITT
population, with distributions estimated using the
Kaplan-Meier method. Unstratified log-rank tests were
used for comparisons between the bortezomib-rituximab
and rituximab arms for high-risk patients and for
patients with high FLIPI score or high tumor burden (P-
values <0.05 were considered statistically significant). A
Cox regression model was used for estimation of HRs
and 95% CIs. ORR, CR rate, and DOR were analyzed in
the response-evaluable population, which included all
patients who received at least one dose of study drug,
had at least one measurable tumor mass at baseline, and
had at least one post-baseline response assessment by
IRC. DOR was analyzed by the Kaplan-Meier method.
The safety population comprised all patients who
received at least one dose of study drug. Statistical ana-
lyses were performed with SAS software, version 9.1.3.
The LYM3001 study is registered with ClinicalTrials.gov,
number NCT00312845.Abbreviations
AE: Adverse event; CI: Confidence interval; CR: Complete response;
CRu: Unconfirmed complete response; CT: Computed tomography;
DOR: Duration of response; FL: Follicular lymphoma; FLIPI: Follicular
Lymphoma International Prognostic Index; GELF: Groupe d’Etude des
Lymphomas Folliculaires; HR: Hazard ratio; IRC: Independent radiology
committee; ITT: Intention-to-treat; LDH: Lactate dehydrogenase;
MRI: Magnetic resonance imaging; NCI-CTCAE: National Cancer Institute
Common Terminology Criteria for Adverse Events; NHL: Non-Hodgkin’s
lymphoma; ORR: Overall response rate; OS: Overall survival; PFS: Progression-
free survival; TFI: Treatment-free interval; TTNT: Time to next anti-lymphoma
treatment; TTP: Time to progression; WHO: World Health Organization;
PR: partial response.Competing interests
PLZ: no competing interests to declare; NKK: no competing interests to
declare; HW: no competing interests to declare; BG: no competing interests
to declare; JW: research and travel grants, and lecture honoraria, Roche; AVH:
no competing interests to declare; PS: no competing interests to declare; DC:
no competing interests to declare; RB: consultancy, Celgene, Novartis, GSK;
DLE: employment, Millennium Pharmaceuticals, Inc., stock ownership,
Johnson & Johnson; PT: employment, Janssen, stock ownership, Johnson &
Johnson; CE: employment, Janssen, stock ownership, Johnson & Johnson; EZ:
employment, Janssen, stock ownership, Johnson & Johnson; YAE:
employment, Janssen, stock ownership, Johnson & Johnson; BC: consulting
fees/honoraria, travel support, Johnson & Johnson, consultancy, Roche,
Amgen, Sanofi, Pfizer, Millennium Pharmaceuticals, Inc., Celgene,
Pharmacyclics, MedImmune, and CTI.
Authors’ contributions
D-LE, PT, YAE, and BC were involved in the design of the study. PLZ, NKK,
HW, BG, JW, AVH, PS, DC, RB, and BC recruited and treated patients for this
study. PLZ, NKK, HW, BG, JW, AVH, PS, DC, RB, PT, CE, EZ, YAE, and BC were
involved in data collection and collation. EZ did statistical analyses of the
data. PLZ, D-LE, PT, CE, YAE, and BC were involved in interpreting the data.
PLZ, PT, CE, EZ, YAE, and BC were involved in writing the draft of the report.
All authors reviewed the draft manuscript and provided critical feedback. All
authors reviewed and approved the final draft of the manuscript.
Financial support
This research was funded by Johnson & Johnson Pharmaceutical Research &
Development, L.L.C. and Millennium Pharmaceuticals, Inc.
Acknowledgments
The authors would like to acknowledge the writing support of Steve Hill of
FireKite during the development of this publication, which was funded by
Millennium Pharmaceuticals, Inc., and Janssen Global Services.
Author details
1Institute of Hematology and Medical Oncology ‘L. & A. Seràgnoli’, University
of Bologna, Bologna, Italy. 2Hematology, SP Botkin Moscow City Hospital,
Moscow, Russia. 3Medical Oncology, Medical University Cancer Hospital,
Tianjin, China. 4Hematology, Hospital Sao Lucas, Porto Alegro, Brazil.
5Hematology, Maria Sklodowska-Curie Memorial Institute and Oncology
Centre, Warsaw, Poland. 6Hematology, Hospital St Jan AV, Brugge, Belgium.
7Medical Oncology, Institut Bergonié, Bordeaux, France. 8Clinical Hematology,
Hospital Clínico de Salamanca, Salamanca, Spain. 9Medical Oncology &
Hematology, Sunnybrook Regional Cancer Center, Toronto, Canada. 10Clinical
Development, Millennium Pharmaceuticals, Inc, Cambridge, MA, USA.
11Oncology R&D, Janssen R&D, High Wycombe, UK. 12Oncology R&D, Janssen
R&D, Raritan, NJ, USA. 13Hematology, Hospices Civils de Lyon, Lyon, France.
Received: 30 August 2012 Accepted: 18 October 2012
Published: 22 October 2012
References
1. Friedberg JW: Treatment of follicular non-Hodgkin's lymphoma: the old
and the new. Semin Hematol 2008, 45:S2–S6.
2. Kenkre VP, Kahl BS: Follicular lymphoma: emerging therapeutic strategies.
Expert Rev Hematol 2010, 3:485–495.
3. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier
P, Bouabdallah R, Catalano JV, Brice P, et al: Rituximab maintenance for 2
years in patients with high tumour burden follicular lymphoma
responding to rituximab plus chemotherapy (PRIMA): a phase 3,
randomised controlled trial. Lancet 2011, 377:42–51.
4. Ghielmini M: Follicular lymphoma. Ann Oncol 2010, 21:vii151–vii153.
5. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera
J, Rodriguez MA, Tsimberidou AM, Verstovsek S, et al: Improvement of
overall and failure-free survival in stage IV follicular lymphoma: 25 years
of treatment experience at The University of Texas M.D. Anderson
Cancer Center. J Clin Oncol 2006, 24:1582–1589.
6. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U,
Pro B, Pileri S, Pulsoni A, Soubeyran P, et al: Follicular lymphoma
international prognostic index 2: a new prognostic index for follicular
Zinzani et al. Journal of Hematology & Oncology 2012, 5:67 Page 9 of 10
http://www.jhoonline.org/content/5/1/67lymphoma developed by the international follicular lymphoma
prognostic factor project. J Clin Oncol 2009, 27:4555–4562.
7. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Rranz-Saez R, Au
WY, Bellei M, Brice P, Caballero D, et al: Follicular lymphoma international
prognostic index. Blood 2004, 104:1258–1265.
8. Luminari S, Cox MC, Montanini A, Federico M: Prognostic tools in follicular
lymphomas. Expert Rev Hematol 2009, 2:549–562.
9. Solal-Celigny P, Cahu X, Cartron G: Follicular lymphoma prognostic factors
in the modern era: what is clinically meaningful? Int J Hematol 2010,
92:246–254.
10. Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camos M, Villela L,
Bosch F, Esteve J, Cervantes F, et al: Predictive value of Follicular
Lymphoma International Prognostic Index (FLIPI) in patients with
follicular lymphoma at first progression. Ann Oncol 2004, 15:1484–1489.
11. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G:
Utility of the Follicular Lymphoma International Prognostic Index and
the International Prognostic Index in assessing prognosis and predicting
first-line treatment efficacy in follicular lymphoma patients. Acta
Haematol 2009, 122:193–199.
12. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N,
Tilly H, Tabah I, Solal-Celigny P: Comparison in low-tumor-burden follicular
lymphomas between an initial no-treatment policy, prednimustine, or
interferon alfa: a randomized study from the Groupe d'Etude des
Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol 1997, 15:1110–1117.
13. Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H,
Feugier P, Ferme C, Copin MC, Lamy T: Efficacy and safety of the
combination of rituximab, fludarabine, and mitoxantrone for rituximab-
naive, recurrent/refractory follicular non-Hodgkin lymphoma with high
tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des
Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et
Autres Maladies du Sang (GOELAMS). Cancer 2010, 116:4299–4308.
14. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M,
Liberati M, Boccomini C, Niscola P, et al: Prognosis of follicular lymphoma:
a predictive model based on a retrospective analysis of 987 cases
Intergruppo Italiano Linfomi. Blood 2000, 95:783–789.
15. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD:
Prognostic factors in follicular lymphoma. J Clin Oncol 2010,
28:2902–2913.
16. Rummel M: Reassessing the standard of care in indolent lymphoma: a
clinical update to improve clinical practice. J Natl Compr Canc Netw 2010,
8:S1–S14.
17. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC,
Offner FC, Gomez-Codina J, Belch A, Cunningham D, et al: Phase III study
of R-CVP compared with cyclophosphamide, vincristine, and prednisone
alone in patients with previously untreated advanced follicular
lymphoma. J Clin Oncol 2008, 26:4579–4586.
18. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C,
Hartmann F, Rothmann F, Rohrberg R, et al: The addition of rituximab to a
combination of fludarabine, cyclophosphamide, mitoxantrone (FCM)
significantly increases the response rate and prolongs survival as
compared with FCM alone in patients with relapsed and refractory
follicular and mantle cell lymphomas: results of a prospective
randomized study of the German Low-Grade Lymphoma Study Group.
Blood 2004, 104:3064–3071.
19. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A,
Romaguera JE, Hagemeister FB, Kwak L, et al: The addition of rituximab to
CHOP chemotherapy improves overall and failure-free survival for
follicular grade 3 lymphoma. Ann Oncol 2008, 19:553–559.
20. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby
E, Veer M, Vranovsky A, Holte H, et al: Rituximab maintenance treatment
of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term
outcome of the EORTC 20981 phase III randomized intergroup study.
J Clin Oncol 2010, 28:2853–2858.
21. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr,
Dien PY, Lyons R, Schlegel PJ, et al: Results of a phase 2 study of
bortezomib in patients with relapsed or refractory indolent lymphoma.
Blood 2010, 115:475–480.
22. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J,
Gonen M, Dumitrescu O, Sarasohn D, Butos J, et al: Time to treatment
response in patients with follicular lymphoma treated with bortezomibis longer compared with other histologic subtypes. Clin Cancer Res 2010,
16:719–726.
23. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdullah R, Delarue R, Boue F,
Bron D, Feugier P, Haioun C, et al: Final results of a randomized phase 2
multicenter study of two bortezomib schedules in patients with
recurrent or refractory follicular lymphoma. Groupe d'Etude Des
Lymphomes De l'Adulte (GELA) study FL-05 [abstract]. Blood 2010,
116:338a.
24. Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM,
Matthews J, Strauss S, Montoto S, Johnson P, et al: Weekly versus twice
weekly bortezomib given in conjunction with rituximab, in patients with
recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom
macroglobulinaemia. Br J Haematol 2010, 151:346–353.
25. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR,
Knapp M, Hart L, Patel-Donnelly D, et al: Multicenter randomized phase II
study of weekly or twice-weekly bortezomib plus rituximab in patients
with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
J Clin Oncol 2009, 27:5023–5030.
26. Chiappella A, Pregno P, Zinzani PL, Evangelista A, Fabbri A, Facchetti F,
Ferreri AJM, Franceschetti S, Freilone R, Gargantini L, et al: Weekly infusion
of bortezomib in combination with rituximab in relapsed/refractory
indolent non-follicular and mantle cell lymphoma is safe and effective:
two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi
(IIL) [abstract]. Blood 2010, 116:1617a.
27. Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd
JC, Blum KA: Phase 2 trial of rituximab and bortezomib in patients with
relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011,
117:2442–2451.
28. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S,
Teixeira A, Walewski J, De VS, et al: Bortezomib plus rituximab versus
rituximab alone in patients with relapsed, rituximab-naive or rituximab-
sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol
2011, 12:773–784.
29. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le GS, Delmer A,
Bordessoule D, Tilly H, Corront B, et al: Long-term follow-up of patients
with newly diagnosed follicular lymphoma in the prerituximab era:
effect of response quality on survival–a study from the Groupe d'Etude
des Lymphomes de l'Adulte. J Clin Oncol 2010, 28:822–829.
30. van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen
ML, van Spronsen DJ: Validation, revision and extension of the Follicular
Lymphoma International Prognostic Index (FLIPI) in a population-based
setting. Ann Oncol 2009, 20:1697–1702.
31. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD,
Armitage JO: Long-term outcomes of autologous stem cell
transplantation for follicular non-Hodgkin lymphoma: effect of
histological grade and Follicular International Prognostic Index. Biol Blood
Marrow Transplant 2008, 14:36–42.
32. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U: Newly diagnosed and
relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2011, 22
(Suppl 6):vi59–vi63.
33. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N,
Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, et al: Non-Hodgkin's
lymphomas. J Natl Compr Canc Netw 2011, 9:484–560.
34. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight
J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ: Acquirement of rituximab
resistance in lymphoma cell lines is associated with both global CD20
gene and protein down-regulation regulated at the pretranscriptional
and posttranscriptional levels. Clin Cancer Res 2008,
14:1561–1570.
35. Jazirehi AR, Vega MI, Bonavida B: Development of rituximab-resistant
lymphoma clones with altered cell signaling and cross-resistance to
chemotherapy. Cancer Res 2007, 67:1270–1281.
36. Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K,
Martinez-Maza O, Bonavida B: The NF-kappaB inhibitors (bortezomib and
DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to
apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008,
49:1982–1994.
37. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J,
Lister TA, Bloomfield CD: World Health Organization classification of
neoplastic diseases of the hematopoietic and lymphoid tissues: report of
Zinzani et al. Journal of Hematology & Oncology 2012, 5:67 Page 10 of 10
http://www.jhoonline.org/content/5/1/67the Clinical Advisory Committee meeting-Airlie House, Virginia,
November 1997. J Clin Oncol 1999, 17:3835–3849.
38. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister
TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al: Report of an international
workshop to standardize response criteria for non-Hodgkin's lymphomas
NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
doi:10.1186/1756-8722-5-67
Cite this article as: Zinzani et al.: Bortezomib plus rituximab versus
rituximab in patients with high-risk, relapsed, rituximab-naïve or
rituximab-sensitive follicular lymphoma: subgroup analysis of a
randomized phase 3 trial. Journal of Hematology & Oncology 2012 5:67.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
